<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12190">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02948244</url>
  </required_header>
  <id_info>
    <org_study_id>36298</org_study_id>
    <nct_id>NCT02948244</nct_id>
  </id_info>
  <brief_title>Effect of Creatine Monohydrate on Functional Muscle Strength in Children With FSHD</brief_title>
  <official_title>Effect of Creatine Monohydrate on Functional Muscle Strength and Muscle Mass in Children With FSHD: a Multi-centre, Randomised, Double-blind Placebo-controlled Crossover Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Murdoch Childrens Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Murdoch Childrens Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-centre, randomised, double-blind, placebo-controlled crossover trial will compare
      changes in strength-related motor function following treatment with creatine monohydrate to
      treatment with placebo, as measured by the Motor Function Measure, from baseline to 12
      weeks. Eligible subjects will undergo baseline assessments then will be randomised to either
      creatine monohydrate therapy or placebo for three months, followed by a six week wash-out
      period, then crossover to a further three months of therapy with either placebo or creatine.
      Subjects will undergo clinical assessments and study safety assessments at the beginning and
      end of each treatment period. The study will begin recruitment in early 2017.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2017</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Motor Function Measure for Neuromuscular disease</measure>
    <time_frame>3 months</time_frame>
    <description>Composite functional outcome measure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle Magnetic Resonance Imaging</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Ultrasound Scan</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dual-Energy X-ray Absorptiometry Scan</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance of the Upper Limb Measure</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACTIVILIM</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PedsQL Neuromuscular</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six Minute Walk Test</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FSH-COM</measure>
    <time_frame>3 months</time_frame>
    <description>FSHD specific composite measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FSHD Severity Score</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative muscle strength testing</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GPX3 Level</measure>
    <time_frame>3 months</time_frame>
    <description>Possible biomarker of disease severity in FSHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Step Counter</measure>
    <time_frame>3 months</time_frame>
    <description>Physical activity measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory safety monitoring</measure>
    <time_frame>3 months</time_frame>
    <description>bloods and urine safety testing (urea and electrolytes, urine plasma creatine:creatinine ratios)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Facio-Scapulo-Humeral Dystrophy</condition>
  <condition>FSHD2</condition>
  <condition>FSHD1</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive 3 months of creatine monohydrate followed by a 6 week washout period followed by 3 months of placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive 3 months of placebo followed by a 6 week washout period followed by 3 months of creatine monohydrate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Creatine Monohydrate</intervention_name>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is between the ages of 5 and 18 years inclusive at the time of randomisation;

          -  Has a confirmed genetic diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD)
             types 1 or 2;

          -  Has a legally acceptable representative capable of understanding the informed consent
             document and providing consent on the participant's behalf.

        Exclusion Criteria:

          -  Has clinically significant elevation in plasma creatinine level or unexplained
             hypertension at screening;

          -  Has a prior diagnosis of chronic renal failure;

          -  Has a known hypersensitivity to creatine monohydrate of maltodextrin placebo;

          -  Patients already taking any medications to increase muscle bulk or strength or
             concomitant use of regular sodium valproate, corticosteroids of alpha agonists such
             as salbutamol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian R Woodcock, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Murdoch Children Research Institute/Royal Children Hospital, Melbourne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Monique M Ryan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Murdoch Children Research Institute/Royal Children Hospital, Melbourne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ian R Woodcock, MBBS</last_name>
    <phone>+61 3 9345 5661</phone>
    <email>ian.woodcock@rch.org.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Monique M Ryan</last_name>
    <phone>+61 3 9345 5661</phone>
    <email>neurology.department@rch.org.au</email>
  </overall_contact_backup>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 27, 2016</lastchanged_date>
  <firstreceived_date>October 26, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fshd</keyword>
  <keyword>creatine monohydrate</keyword>
  <keyword>children</keyword>
  <keyword>pediatrics</keyword>
  <keyword>Facio-Scapulo-Humeral Dystrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muscular Dystrophy, Facioscapulohumeral</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
